Role evidence
Usage summary
Strongest role: Unclear
Inclusion-required count: 0
Treatment-assignment count: 0
Stratification count: 0
Low Public Signal
MSI-H / dMMR
melanoma · Monoclonal Antibody
MSI-H / dMMR is flagged as low public signal because public trials show unclear evidence in 1 contexts. FDA CDx context should be reviewed manually.
Threshold snippets
Fragmentation view
Threshold count: 2
Common snippets: MSI-H | MSI-H
Threshold label: Low
FDA CDx context
Mapping summary
CDx label: Fda Cdx Context Manual Review Required
CDx maturity score: 2/5
Confidence: Medium
Patent-density signal
Diagnostic appendix
Signal count: 0
Recent signals: 0
Density label: Low
Source links
Evidence paths
https://clinicaltrials.gov/study/NCT05483400